Innoviva reported for the third quarter of 2026 revenue of $106.1 million, net product sales of $49.4 million and income from operations of $42.2 million, but a net loss of $73.9 million driven by investment fair-value declines; cash and cash equivalents totaled $581.4 million.
INVA · Innoviva, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $18.41
- Open
- $18.31
- Day range
- $18.19–18.56
- 52-week closing range
- $18.30–24.24
- Average volume, 30 days
- 831K
- Short interest
- 7.5M · 10.5% of shares · 12.9 days
- Short volume, last session
- 52%
- Last earnings
- May 8, 2024
- Latest filing
- 10-Q · Nov 4
- Price history
- Jan 2020 to Nov 2026
Latest documents
Innoviva reported third-quarter total revenue of $106.1 million, including $43.3 million of U.S. net product sales, up 45% year over year, but posted a $73.9 million net loss for the quarter ended September 30, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INVA
this stock
Innoviva, Inc.
|
$1.31B | -7.9% | +62.6% | 8.2 | 10.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 14
Innoviva reported for the third quarter of 2026 revenue of $106.1 million, net product sales of $49.4 million and income from operations of $42.2 million, but a net loss of $73.9 million driven by investment fair-value declines; cash and cash equivalents totaled $581.4 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INVA | -3.0% | -12.6% | -14.4% | -13.2% | -7.9% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +2.5% | -6.3% | -8.8% | -8.0% | -12.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.